Rosetta Genomics Achieves Major Commercial Milestone by Obtaining Medicare Coverage of miRview mets2 Assay

Medicare Beneficiaries to Gain Access to Proprietary Test to Identify Tumor Origin in Cancer of Unknown and Uncertain Primary

Rosetta Genomics Ltd. (ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, today announced that Novitas, the designated Medicare Administrative Contractor for the Company's miRview® mets² assay, has informed Rosetta that it plans to cover this assay for all Medicare beneficiaries. MiRview® mets² accurately identifies the primary tumor of origin in primary and metastatic cancer including Cancer of Unknown or Uncertain Primary ("CUP").

Vermillion Receives Notice of Allowance for Patent on Methods for Diagnosing Ovarian Cancer

Vermillion, Inc. (NASDAQ: VRML - News), a leading molecular diagnostics company, has received a notice of allowance from the United States Patent and Trademark Office for a patent, "Methods for Diagnosing Ovarian Cancer."

This patent further expands the list of biomarkers Vermillion has employed in the diagnosis or status determination of ovarian cancer. In this case, the granted claims cover the use of Protein C Inhibitor (PCI) in ovarian cancer tests using blood and several other sample types.

TearLab to Present at the 24th Annual ROTH Conference

TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") announced today that its Chief Scientific Officer, Benjamin Sullivan, Ph.D., will present an update on the Company's business at the 24th Annual ROTH Conference on Wednesday, March 14, 2012 at 12:00 p.m. Pacific Time. The conference will be held at The Ritz Carlton in Dana Point, CA.

Dr. Sullivan's presentation will be webcast live and archived for at least 30 days on the Company's website at http://www.tearlab.com under the "Webcasts" tab in the Investors section.

Miraculins Outlines Details of PreVu 510(k) FDA Clearance

Miraculins Inc. (TSX VENTURE:MOM.V - News), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, today outlined the details of the FDA clearance for its PreVu(R) Non-Invasive Skin Cholesterol Point of Care (POC) Test. The FDA clearance was issued prior to Miraculins' acquisition of the PreVu technology and remains in effect in the U.S. marketplace.

"With the recent, significant announcements that the PreVu POC Test has been cleared for sale by Health Canada and has been CE-Marked for sale in the European Union, Management believes it is important to remind the market that an FDA clearance for the PreVu POC Test was in place at the time of our acquisition and was one of the key considerations in our decision to purchase PreVu," said Christopher J. Moreau, President and CEO of Miraculins.